Rein Therapeutics provides update on RENEW clinical trial

Rein Therapeutics (RNTX) provided an update on its ongoing Phase 2 RENEW clinical trial evaluating LTI-03 for the treatment of idiopathic pulmonary fibrosis. The company said, “The Company has enrolled 8 patients in its RENEW trial to date, with 2 additional patients expected to be enrolled this week. Enrollment in the study began in March 2026, and the Company continues to add patients on a regular basis. Rein also continues to make progress on expanding its global clinical trial footprint. Clinical trial sites are currently active in the United States, Australia, and Poland, with additional countries – including the United Kingdom and Germany – expected to open in the near term. The Company plans to continue activating more new sites to support ongoing enrollment.”